Kingdom Capital Collaborates with Washington University School of Medicine to Launch Augmented Intelligence Company PercayAI

  • PercayAI, launched by Kingdom Capital, represents the investment firmโ€™s commitment to cultivating new technologies that can help accelerate drug discovery and improve patient outcomes.
  • Washington University School of Medicine in St. Louis will continue to develop technology that will be commercialized through PercayAI as part of an ongoing collaboration with Kingdom Capital.

Values-driven investment firm, Kingdom Capital, today announced the launch of PercayAI, an augmented intelligence software company that helps researchers develop new drugs more quickly and successfully.

The first product available from PercayAI is CompBio, software co-developed with the Genome Technology Access Center at the McDonnell Genome Institute ([email protected]) at Washington University School of Medicine in St. Louis. Using a unique combination of contextual language processing and artificial intelligence, CompBio can mimic the thought processes of biological science experts, rapidly identifying non-obvious relationships within complex, -omic and multi-omic biological data sets.

CompBioโ€™s interface uses an intuitive, interactive 3D format that allows researchers to easily view all the information specific to their biological paradigm, helping scientists to have a greater understanding of the biology driving their research. During development, CompBioโ€™s capabilities were validated by the GTAC through testing with more than 40 laboratories, including one led by microbiome research pioneer and 2018 Copley Medal recipient Dr. Jeffrey Gordon of Washington University, resulting in the first of several upcoming publications using CompBio in peer reviewed journal articles.

โ€œPercayAI represents a foundational suite of technologies to further Kingdom Capitalโ€™s mission to benefit patients and their families,โ€ said Scott Glover, President Health & Medical sector. โ€œAs a values-driven investment firm, our investments address unmet or under-resourced needs, and PercayAI will play an important role in helping to accelerate drug discovery, leading to new medicines and better patient outcomes faster.โ€

โ€œWith this software, researchers can organize and prioritize relevant data in ways that arenโ€™t possible with other tools, improving the speed, cost and success rate of diagnostic and drug development,โ€ said Preston Keller, Director and Chief Commercial Officer at PercayAI. โ€œPercayAI is committed to helping researchers enhance patientsโ€™ quality of life, providing them with innovative technological solutions that advance the drug development process.โ€

โ€œAs we continue to advance the CompBio platform, there has been a convergence of neural networks, deep learning and advanced heuristics with a novel model of contextual memory creation that enables rapid knowledge generation and assimilation. Scaling tasks well beyond that of normal human limitations, the power and potential of this Augmented Intelligence system arises from pairing humans and machines, so that the human โ€“ a drug researcher in this case – is learning from the machine and, at the same time, the machine is learning from the human,โ€ said Professor Richard Head, Director of GTAC at Washington University School of Medicine. โ€œWeโ€™re leveraging this in CompBio to allow researchers to explore the biological landscape and rapidly uncover insights at every stage of the drug R&D process.โ€

Leave a Reply